POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: xasxas on March 12, 2013, 11:57:09 am
-
This may be old news as this compound has been around for a while but I found it exciting as it has the potential to be an eradicative cure.
http://www.prweb.com/releases/2010/02/prweb3532854.htm
-
It is indeed old news.
Latent reservoirs cleaning ''substances'' need to be tested, and it can take 10 years or more.
So, why not use meds that are considered safe, and are already widely used in clinical settings, like
1) Disulfiram /Antabuse
http://en.wikipedia.org/wiki/Disulfiram
RESULTS:
DSF reactivated latent HIV-1 expression in the U1 cell line, but not in the J89GFP or ACH2 cell lines. Interestingly, we found that DSF significantly reduced phosphatase and tensin homolog (PTEN) protein levels in U1 cells and in resting CD4 T cells from HIV-negative donors. Decreased PTEN resulted in increased phosphorylation of protein kinase B (Akt) and activation of the Akt signaling pathway. Consistent with these finding, pharmacological inhibitors of Akt and nuclear factor-kappaB (NF-κB) block the latent HIV-1-reactivating activity of DSF. Furthermore, we show that HIV-1 expression in the U1 cell line could be activated by a small molecule inhibitor of PTEN or by siRNA knockdown of PTEN expression. Neither the J89GFP nor ACH2 cells express PTEN, explaining the lack of DSF effect on HIV-1 expression in both these cell lines.
CONCLUSION: DSF reactivates latent HIV-1 expression via the Akt signaling pathway through depletion of PTEN.
http://www.ncbi.nlm.nih.gov/pubmed/22739395
2) Miltefosine / Impavido
http://en.wikipedia.org/wiki/Miltefosine
Miltefosine targets HIV infected macrophages, which play a role in vivo as long-lived HIV-1 reservoirs. The HIV protein Tat activates pro-survival PI3K/Akt pathway in primary human macrophages. Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the infected macrophages from circulation, without affecting healthy cells.